Home > Insider Trading > Filing (0001209191-22-030549)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1698530	Exicure Inc.	XCUR	Pharmaceutical Preparations (2834)	815333008

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1784138	Bali Muralidhar	C/O Exicure, Inc. 2430 N. Halsted Street Chicago IL 60614		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-05-19	1,472,126	$0.19	8,449,126	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes

Footnotes

The shares are held by Abingworth Bioventures VII LP ("Abingworth VII"). Abingworth Bioventures VII GP LP serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, (together with Abingworth Bioventures VII GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures VII GP LP. Abingworth VII (acting by its general partner Abingworth Bioventures VII GP LP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth VII. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth VII.
Each of Abingworth VII, Abingworth LLP, the General Partners, the Reporting Person and each member of the investment committee disclaims beneficial ownership of the common stock held by Abingworth VII, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.